文献速递乳腺癌放疗

新辅助同步放化疗对局部晚期不可手术乳腺癌可手术性与生存的影响

Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-29

本研究纳入2017年5月至2021年12月期间202例III期不可手术局部晚期乳腺癌女性患者,接受4周期多柔比星联合环磷酰胺和4周期紫杉醇化疗,同步放疗总剂量46 Gy。88.1%患者接受改良根治术,其中36.5%达到病理完全缓解;中位随访42个月,4年无事件生存率和总生存率分别为63.4%和71.5%。

要点

  • 88.1%不可手术局部晚期乳腺癌患者经新辅助同步放化疗后接受改良根治术,8.5%仍不可手术。
  • 接受改良根治术患者中36.5%达到病理完全缓解,激素受体阳性、三阴性、HER2阳性分别为16%、45.6%、60.7%。
  • 中位随访42个月,4年无事件生存率和总生存率分别为63.4%和71.5%。

核心结论

  • 新辅助同步放化疗可改善不可手术局部晚期乳腺癌患者的可手术性和生存结局。

研究设计与样本

  • 研究于2017年5月至2021年12月招募III期不可手术局部晚期乳腺癌患者。
  • 治疗方案包括4周期多柔比星联合环磷酰胺和4周期紫杉醇化疗,同步放疗总剂量46 Gy。
  • 治疗后评估手术,并根据受体状态给予额外治疗,分析病理完全缓解、可手术性和生存。

主要发现

  • 共纳入202例女性患者,中位年龄52岁;IIIA期23.7%,IIIB期65.3%,IIIC期10.8%。
  • 激素受体阳性44.6%,三阴性乳腺癌24.8%,HER2阳性30.7%。
  • 88.1%患者接受改良根治术,8.5%仍不可手术,3.4%拒绝手术;接受改良根治术者中36.5%达到病理完全缓解。
  • 接受改良根治术患者均实现完整切除且切缘阴性;病理完全缓解率在激素受体阳性、三阴性、HER2阳性患者中分别为16%、45.6%、60.7%。
  • 3级皮肤反应发生率19.3%,需住院的术后伤口并发症发生率10.6%;中位随访42个月,4年无事件生存率和总生存率分别为63.4%和71.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Inoperable locally advanced breast cancers (LABCs) are treated with neoadjuvant chemotherapy. We studied the use of neoadjuvant concurrent chemoradiation (NACCRT) in patients with inoperable LABC. METHODS AND MATERIALS: From May 2017 to December 2021, the study recruited patients with stage III inoperable LABC. Treatment included 4 cycles of doxorubicin and cyclophosphamide and 4 cycles of paclitaxel, along with concurrent radiation therapy to a total dose of 46 Gy. Thereafter, all patients were evaluated for surgery, and additional treatments were given based on receptor status. The effects of NACCRT on pathologic complete response (pCR), operability, and survival were analyzed. RESULTS: The study involved 202 female patients with a median age of 52 years. Of these, 23.7% had IIIA, 65.3% had IIIB, and 10.8% had IIIC disease. Hormone receptor-positive disease was observed in 44.6% of patients, triple-negative breast cancer was observed in 24.8% of patients, and Human epidermal growth factor receptor 2 (HER2)-positive disease was observed in 30.7% of patients. Modified radical mastectomy (MRM) was performed in 88.1% of patients, 8.5% of patients remained inoperable, and 3.4% of patients declined surgery. Among the patients who underwent MRM, 36.5% of patients had a pCR. Patients who were operable and underwent MRM had complete resections and had negative margins. pCR was observed in 16% with hormone receptor-positive disease, in 45.6% with triple-negative breast cancer, and in 60.7% with HER2-positive disease. Grade 3 skin reactions were observed in 19.3% of patients. Postoperative wound morbidity requiring hospitalization was observed in 10.6% of patients. After a median follow-up of 42 months, the 4-year event-free survival and overall survival rates were 63.4% and 71.5%, respectively. HER2-positive patients who achieved a pCR had significantly improved event-free survival and overall survival. CONCLUSIONS: Our study shows that using NACCRT can improve operability and survival outcomes in patients with inoperable LABC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Iyer P, Krishnamurthy A, Velusamy S, et al. Effect of Neoadjuvant Concurrent Chemoradiation on Operability and Survival in Locally Advanced Inoperable Breast Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 38036271. doi:10.1016/j.ijrobp.2023.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。